Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Repare Therapeutics Inc. (RPTX).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Sep 2021, 18:18.
ORBIMED ADVISORS LLC - 03 Sep 2021 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)
- Reporting relationship
- Director
- Issuer ticker
- RPTX
- Reported as of
- 03 Sep 2021
- Net transaction value
- -$274,794
- SEC form
- 4
- Accepted by SEC
- 08 Sep 2021, 18:18:30 UTC
- Prior SEC filing
- 02 Sep 2021
- Next SEC filing
- 21 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- OrbiMed Advisors LLC, /s/ Douglas Coon, Chief Compliance Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Repare Therapeutics Inc. (RPTX) on 08 Sep 2021.
Change
- Previous filing in this sequence was filed on 02 Sep 2021.
- Current net transaction value: -$274,794.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPTX
transaction
Common Stock
Sale
- Transaction value
- $237,490
- Shares
- -6,985
- Change %
- -0.22%
- Price
- $34.00
- Shares after
- 3,177,902
- Date
- 03 Sep 2021
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F5
RPTX
transaction
Common Stock
Sale
- Transaction value
- $7,208
- Shares
- -212
- Change %
- -0.22%
- Price
- $34.00
- Shares after
- 96,216
- Date
- 03 Sep 2021
- Ownership
- See Footnotes
- Footnotes
- F3, F4, F5
RPTX
transaction
Common Stock
Sale
- Transaction value
- $29,214
- Shares
- -861
- Change %
- -0.03%
- Price
- $33.93
- Shares after
- 3,177,041
- Date
- 07 Sep 2021
- Ownership
- See Footnotes
- Footnotes
- F2, F5, F6
RPTX
transaction
Common Stock
Sale
- Transaction value
- $882
- Shares
- -26
- Change %
- -0.03%
- Price
- $33.93
- Shares after
- 96,190
- Date
- 07 Sep 2021
- Ownership
- See Footnotes
- Footnotes
- F4, F5, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
These shares of the Issuer's common stock were sold in a block order at price of $34.00 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP ("OPI VII").
Footnote F2
These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
Footnote F3
These shares of the Issuer's common stock were sold in a block order at price of $34.00 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited ("OPM").
Footnote F4
These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.
Footnote F5
This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
Footnote F6
These shares of the Issuer's common stock were sold in a block order at price of $33.93 pursuant to a Rule 10b5-1 trading plan established by OPI VII.
Footnote F7
These shares of the Issuer's common stock were sold in a block order at price of $33.93 pursuant to a Rule 10b5-1 trading plan established by OPM.